M. Brawner Floyd

7.7k total citations · 1 hit paper
41 papers, 2.3k citations indexed

About

M. Brawner Floyd is a scholar working on Organic Chemistry, Molecular Biology and Oncology. According to data from OpenAlex, M. Brawner Floyd has authored 41 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Organic Chemistry, 12 papers in Molecular Biology and 11 papers in Oncology. Recurrent topics in M. Brawner Floyd's work include HER2/EGFR in Cancer Research (9 papers), Quinazolinone synthesis and applications (9 papers) and Synthesis and biological activity (5 papers). M. Brawner Floyd is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Quinazolinone synthesis and applications (9 papers) and Synthesis and biological activity (5 papers). M. Brawner Floyd collaborates with scholars based in United States and Canada. M. Brawner Floyd's co-authors include Bernard D. Johnson, Allan Wissner, Ramaswamy Nilakantan, Ru Shen, Hwei‐Ru Tsou, Marvin F. Reich, Sridhar K. Rabindran, Carolyn Discafani, Yu‐Fen Wang and William Hallett and has published in prestigious journals such as Journal of the American Chemical Society, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

M. Brawner Floyd

40 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

2004 503 citations Sridhar K. Rabindran, Carolyn Discafani et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Brawner Floyd United States	20	1.1k	926	921	425	278	41	2.3k
Marvin F. Reich United States	14	769 0.7×	750 0.8×	841 0.9×	450 1.1×	271 1.0×	21	1.8k
Hwei‐Ru Tsou United States	17	823 0.8×	792 0.9×	882 1.0×	417 1.0×	278 1.0×	24	1.9k
Dennis J. McNamara United States	18	646 0.6×	1.1k 1.2×	807 0.9×	450 1.1×	180 0.6×	28	2.0k
Karen Lackey United States	21	883 0.8×	1.3k 1.4×	1.3k 1.4×	516 1.2×	448 1.6×	32	2.8k
H. D. Hollis Showalter United States	26	1.4k 1.3×	1.1k 1.2×	718 0.8×	229 0.5×	180 0.6×	64	2.5k
Scott H. Dickerson United States	19	778 0.7×	1.2k 1.2×	880 1.0×	330 0.8×	266 1.0×	29	2.2k
Giorgio Caravatti Switzerland	26	660 0.6×	1.5k 1.6×	713 0.8×	213 0.5×	149 0.5×	45	2.3k
Gregory D. Vite United States	28	1.0k 1.0×	1.3k 1.4×	1.1k 1.2×	206 0.5×	335 1.2×	64	2.8k
Carolyn Discafani United States	23	872 0.8×	1.4k 1.5×	1.4k 1.5×	569 1.3×	357 1.3×	30	3.0k
Wilson B. Knight United States	23	319 0.3×	1.0k 1.1×	770 0.8×	253 0.6×	290 1.0×	46	1.9k

Countries citing papers authored by M. Brawner Floyd

Since Specialization

Citations

This map shows the geographic impact of M. Brawner Floyd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Brawner Floyd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Brawner Floyd more than expected).

Fields of papers citing papers by M. Brawner Floyd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Brawner Floyd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Brawner Floyd. The network helps show where M. Brawner Floyd may publish in the future.

Co-authorship network of co-authors of M. Brawner Floyd

This figure shows the co-authorship network connecting the top 25 collaborators of M. Brawner Floyd. A scholar is included among the top collaborators of M. Brawner Floyd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Brawner Floyd. M. Brawner Floyd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wodicka, Lisa, Pietro Ciceri, Mindy I. Davis, et al.. (2010). Activation State-Dependent Binding of Small Molecule Kinase Inhibitors: Structural Insights from Biochemistry. Chemistry & Biology. 17(11). 1241–1249. 82 indexed citations

Nittoli, Thomas, Russell G. Dushin, M. Brawner Floyd, et al.. (2009). The identification of 8,9-dimethoxy-5-(2-aminoalkoxy-pyridin-3-yl)-benzo[c][2,7]naphthyridin-4-ylamines as potent inhibitors of 3-phosphoinositide-dependent kinase-1 (PDK-1). European Journal of Medicinal Chemistry. 45(4). 1379–1386. 21 indexed citations

Wissner, Allan, Russell G. Dushin, M. Brawner Floyd, et al.. (2007). Dual irreversible kinase inhibitors: Quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2. Bioorganic & Medicinal Chemistry. 15(11). 3635–3648. 62 indexed citations

Tsou, Hwei‐Ru, William Hallett, Marvin F. Reich, et al.. (2005). Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity. Journal of Medicinal Chemistry. 48(4). 1107–1131. 246 indexed citations

Berger, Dan, Minu Dutia, Dennis Powell, et al.. (2003). Synthesis and evaluation of 4-Anilino-6,7-dialkoxy-3-quinolinecarbonitriles as inhibitors of kinases of the Ras-MAPK signaling cascade. Bioorganic & Medicinal Chemistry Letters. 13(18). 3031–3034. 25 indexed citations

Wissner, Allan, Marvin F. Reich, M. Brawner Floyd, et al.. (2002). Synthesis and Structure−Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2). Journal of Medicinal Chemistry. 46(1). 49–63. 212 indexed citations

Wissner, Allan, M. Brawner Floyd, Sridhar K. Rabindran, et al.. (2002). Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents. Bioorganic & Medicinal Chemistry Letters. 12(20). 2893–2897. 54 indexed citations

Wang, Yanong D., Karen Miller, Diane H. Boschelli, et al.. (2001). ChemInform Abstract: Inhibitors of Src Tyrosine Kinase: The Preparation and Structure—Activity Relationship of 4‐Anilino‐3‐cyanoquinolines and 4‐Anilinoquinazolines.. ChemInform. 32(7). 1 indexed citations

Wang, Yanong D., Karen Miller, Diane H. Boschelli, et al.. (2000). Inhibitors of Src tyrosine kinase: the preparation and structure–activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines. Bioorganic & Medicinal Chemistry Letters. 10(21). 2477–2480. 58 indexed citations

10.

Discafani, Carolyn, Marion L. Carroll, M. Brawner Floyd, et al.. (1999). Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with In Vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785). Biochemical Pharmacology. 57(8). 917–925. 84 indexed citations

11.

Birnbaum, Jay E., Peter Cervoni, Peter S. Chan, et al.. (1982). Prostaglandins and congeners. 29. (16RS)-(.+-.)-15-Deoxy-16-hydroxy-16-vinylprostaglandin E2, an orally and transdermally active hypotensive agent of prolonged duration. Journal of Medicinal Chemistry. 25(5). 492–494. 15 indexed citations

12.

Floyd, M. Brawner & Martin J. Weiss. (1979). Prostaglandins and congeners. 21. Synthesis of some cyclohexyl analogs (11.alpha.-homoprostaglandins). The Journal of Organic Chemistry. 44(1). 71–75. 14 indexed citations

13.

Floyd, M. Brawner, et al.. (1979). Prostaglandins and congeners. 20. Synthesis of prostaglandins via conjugate addition of lithium trans-1-alkenyltrialkylalanate reagents. A novel reagent for conjugate 1,4-additions. The Journal of Organic Chemistry. 44(9). 1438–1447. 144 indexed citations

14.

Floyd, M. Brawner. (1978). Prostaglandins and congeners. 18. Synthesis of cyclopentenolone precursors to prostaglandins from 2,5-dihydro-2,5-dimethoxyfurans. The Journal of Organic Chemistry. 43(9). 1641–1643. 22 indexed citations

15.

Floyd, M. Brawner. (1974). A Synthesis of 2-(6′-Carboxy-2′-cis-Hexenyl)-4-Hydroxycyclopent-2-EN-1-ONE, a Prostagiandin Intermediate¹. Synthetic Communications. 4(6). 317–323. 12 indexed citations

16.

Floyd, M. Brawner & Martin J. Weiss. (1973). Synthesis of prostaglandins by alanate additions to cyclopentenones (1). Prostaglandins. 3(6). 921–924. 10 indexed citations

17.

Floyd, M. Brawner & George R. Allen. (1970). Cyclic Analog of Ethacrynic Acid. Journal of Pharmaceutical Sciences. 59(6). 869–870.

18.

Gensler, Walter J., et al.. (1970). Synthesis of methyl sterculate. Journal of the American Chemical Society. 92(8). 2472–2475. 12 indexed citations

19.

Gensler, Walter J., et al.. (1970). Syntheses of methyl malvalate and methyl 5-6-methano-5-undecenoate. The Journal of Organic Chemistry. 35(7). 2301–2307. 10 indexed citations

20.

Wasserman, Harry H. & M. Brawner Floyd. (1963). On the autoxidation of indoles. Tetrahedron Letters. 4(29). 2009–2012. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact